Oncolytic Viruses: A Novel Treatment Strategy for Breast Cancer

Overview

Journal Genes Dis

Date 2023 May 24

PMID 37223527

Authors

Mohammad Javanbakht

Sanaz Tahmasebzadeh

Luca Cegolon

Nasrin Gholami

Mandana Kashaki

Hassan Nikoueinejad

Mohamad Mozafari

Mahsa Mozaffari

Shi Zhao

Mostafa Khafaei

Morteza Izadi

Saeid Fathi

Reza Akhavan-Sigari

Affiliations

Soon will be listed here.

Abstract

Breast cancer, an unceasingly occurring neoplasm, is one of the major determinants of mortality in women. Several ineffective attempts have been pursued using with conventional therapies against breast cancer. Resistance to existing therapies and their respective debilitating adverse effects have led research toward a new era of cancer treatment using viruses. Virotherapy constitutes a developing treatment modality with multiple mechanisms of therapeutic activity in which the viruses can be directly oncolyticand can express transgenes or induce host immune response against tumor cells. Several different DNA- and RNA-containing viruses have been considered for virotherapy of breast cancer including adenovirus, herpes virus, vaccinia, reovirus, Newcastle Disease virus, measles virus and vesicular stomatitis virus. This review aims to summarize the viro-therapeutical agents against breast malignancies. Key Scientific Concepts of Review: In this review paper, we proposed a new strategy to virus's combinatorial treatments using several kinds of transgenes and drugs. These recombinant viruses have provided evidence of treatment efficacy against human breast cancer.

Citing Articles

An in silico approach uncovering the competency of oncolytic human adenovirus 52 for targeted breast cancer virotherapy.

Naveed M, Batool Z, Aziz T, Javed K, Ali N, Rehman H Sci Rep. 2024; 14(1):26405.

PMID: 39488601 PMC: 11531525. DOI: 10.1038/s41598-024-77664-4.

Advancements in Immunotherapy for Breast Cancer: Mechanisms, Efficacy, and Future Directions.

Rai A, Deshpande S, Vaidya A, Shinde R Cureus. 2024; 16(8):e68351.

PMID: 39355073 PMC: 11443072. DOI: 10.7759/cureus.68351.

A novel approach for breast cancer treatment: the multifaceted antitumor effects of rMeV-Hu191.

Zheng X, Lv Y, Xu L, Zhou D, Yu L, Zhao Z Hereditas. 2024; 161(1):36.

PMID: 39342391 PMC: 11439206. DOI: 10.1186/s41065-024-00337-9.

Antimetastatic and antitumor activities of oncolytic NDV AMHA1 in a 3D culture model of breast cancer.

Al-Shammari A, Salman M Front Mol Biosci. 2024; 11:1331369.

PMID: 39281317 PMC: 11392722. DOI: 10.3389/fmolb.2024.1331369.

Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments.

Yan Z, Zhang Z, Chen Y, Xu J, Wang J, Wang Z Cancer Cell Int. 2024; 24(1):242.

PMID: 38992667 PMC: 11238399. DOI: 10.1186/s12935-024-03424-z.

References

Lien-Anh Nguyen T, Fonseca Tumilasci V, Singhroy D, Arguello M, Hiscott J . The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies. Cell Microbiol. 2009; 11(6):889-97. DOI: 10.1111/j.1462-5822.2009.01317.x. View

Jamal M, Chng W, Yusoff K, Shafee N . Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization. Cancer Cell Int. 2012; 12(1):35. PMC: 3495217. DOI: 10.1186/1475-2867-12-35. View

Zeng W, Li J, Hu P, Lei L, Wang J, Liu R . An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer. Oncol Rep. 2013; 29(6):2355-61. DOI: 10.3892/or.2013.2359. View

Fujiyuki T, Yoneda M, Amagai Y, Obayashi K, Ikeda F, Shoji K . A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells. Oncotarget. 2015; 6(28):24895-903. PMC: 4694801. DOI: 10.18632/oncotarget.4366. View

Mohebtash M, Tsang K, Madan R, Huen N, Poole D, Jochems C . A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2011; 17(22):7164-73. PMC: 3227395. DOI: 10.1158/1078-0432.CCR-11-0649. View

Rodriguez Stewart R, Berry J, Berger A, Yoon S, Hirsch A, Guberman J . Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors. J Virol. 2019; 93(23). PMC: 6854488. DOI: 10.1128/JVI.01411-19. View

Zamarin D, Palese P . Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol. 2012; 7(3):347-67. PMC: 4241685. DOI: 10.2217/fmb.12.4. View

Yang C, Chen H, Yu L, Shan L, Xie L, Hu J . Inhibition of FOXM1 transcription factor suppresses cell proliferation and tumor growth of breast cancer. Cancer Gene Ther. 2013; 20(2):117-24. DOI: 10.1038/cgt.2012.94. View

Fasullo M, Burch A, Britton A . Hypoxia enhances the replication of oncolytic herpes simplex virus in p53- breast cancer cells. Cell Cycle. 2009; 8(14):2194-7. DOI: 10.4161/cc.8.14.8934. View

10.

Hastie E, Grdzelishvili V . Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol. 2012; 93(Pt 12):2529-2545. PMC: 4091291. DOI: 10.1099/vir.0.046672-0. View

11.

Bishnoi S, Tiwari R, Gupta S, Byrareddy S, Nayak D . Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy. Viruses. 2018; 10(2). PMC: 5850397. DOI: 10.3390/v10020090. View

12.

Kuruppu D, Tanabe K . HSV-1 as a novel therapy for breast cancer meningeal metastases. Cancer Gene Ther. 2015; 22(10):506-8. PMC: 4766812. DOI: 10.1038/cgt.2015.43. View

13.

Chiocca E, Rabkin S . Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014; 2(4):295-300. PMC: 4303349. DOI: 10.1158/2326-6066.CIR-14-0015. View

14.

Parato K, Breitbach C, Le Boeuf F, Wang J, Storbeck C, Ilkow C . The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther. 2011; 20(4):749-58. PMC: 3321594. DOI: 10.1038/mt.2011.276. View

15.

Ahmad U, Ahmed I, Keong Y, Abd Manan N, Othman F . Inhibitory and apoptosis-inducing effects of Newcastle disease virus strain AF2240 on mammary carcinoma cell line. Biomed Res Int. 2015; 2015:127828. PMC: 4363544. DOI: 10.1155/2015/127828. View

16.

Gholami S, Chen C, Gao S, Lou E, Fujisawa S, Carson J . Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer. Cancer Gene Ther. 2014; 21(7):283-9. DOI: 10.1038/cgt.2014.28. View

17.

Schirrmacher V, Van Gool S, Stuecker W . Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy. Biomedicines. 2019; 7(3). PMC: 6783952. DOI: 10.3390/biomedicines7030066. View

18.

Gomez-Navarro J, Curiel D . Conditionally replicative adenoviral vectors for cancer gene therapy. Lancet Oncol. 2002; 1:148-58. DOI: 10.1016/s1470-2045(00)00030-9. View

19.

Li J, Zeng W, Huang Y, Zhang Q, Hu P, Rabkin S . Treatment of breast cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Ther. 2012; 19(10):707-14. PMC: 3444761. DOI: 10.1038/cgt.2012.49. View

20.

Bauerschmitz G, Barker S, Hemminki A . Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). Int J Oncol. 2002; 21(6):1161-74. View